Lisata Therapeutics: SciBase and Castle Biosciences Partner to Transform Atopic Dermatitis Management
- SciBase partners with Castle Biosciences to develop a predictive test for atopic dermatitis flare-ups using Nevisense devices.
- The collaboration aims to enhance dermatologic care and improve patient outcomes for those with chronic skin conditions.
- SciBase will issue shares worth SEK 30 million, emphasizing financial commitment to advancing dermatologic diagnostics and treatment.
SciBase and Castle Biosciences Partner to Revolutionize Atopic Dermatitis Management
SciBase Holding AB, a leader in AI-driven diagnostic solutions, forges a significant partnership with Castle Biosciences, a prominent name in molecular diagnostics, to develop a predictive test for flares in atopic dermatitis (AD). This collaboration, announced on June 17, 2025, leverages SciBase's advanced EIS technology and its Nevisense devices, which are designed to enhance the management of skin disorders. By focusing on creating a test that predicts flare-ups, the two companies aim to provide healthcare professionals and patients with better tools for managing this chronic skin condition, which affects millions worldwide.
The partnership outlines a strategic approach to clinical exploration across multiple regions, including the EU, Switzerland, UAE, Japan, and South Korea, while Castle Biosciences will concentrate on the North American market. This geographic division allows both companies to maximize the potential for growth and accessibility of innovative treatment solutions. As part of the agreement, SciBase plans to issue shares worth approximately SEK 30 million, with Castle committing to invest around SEK 19 million. This financial backing highlights Castle's confidence in the potential of Nevisense to play a critical role in dermatologic care, particularly for patients suffering from atopic dermatitis, a condition known for its unpredictability and significant patient burden.
Pia Renaudin, CEO of SciBase, expresses optimism regarding the collaboration, indicating that it will not only enhance the application of Nevisense in skin barrier health but also accelerate the pace of clinical studies in dermatology. Moreover, the agreement includes a structured financial arrangement where SciBase will defer initial clinical development costs, which will be recuperated through future royalty and milestone payments. These aspects underscore the commitment of both companies to advance dermatologic diagnostics and treatment, ultimately aiming for improved patient outcomes in managing atopic dermatitis.
In addition to the collaborative efforts in atopic dermatitis, the partnership emphasizes the importance of innovation in the dermatology field. With Castle’s established presence in molecular diagnostics, combining their expertise with SciBase’s cutting-edge technology can lead to breakthroughs that significantly enhance patient care. Both companies recognize the global prevalence of atopic dermatitis and the pressing need for effective management strategies, making their collaboration timely and crucial for advancing dermatological health solutions.
As the collaboration unfolds, stakeholders in the dermatology sector closely watch for developments that could reshape approaches to managing chronic skin conditions. The joint efforts of SciBase and Castle Biosciences represent a pivotal move towards integrating advanced technology into everyday clinical practice, potentially setting new standards for patient care in dermatology.